Abstract Orphan drugs have become a central component of pharmaceutical merger and acquisition (M&A) strategy, driven by high unmet medical need, regulatory exclusivity, and comparatively favorable development economics. While the literature has extensively examined market exclusivity and pricing dynamics, less attention has been paid to the role of fiscal incentives in shaping transaction valuation. This […]
Change your region and language
Be sure to pick the location that matches your preferences.
- Industries
- Services
- Not sure what service is tailored for your needs?
- Insights
- Partnerships
- Already a Leyton’s partner?
We’re so happy to be working with you. Explore the resources that come with a Leyton partnership.
- About Leyton
- Empower Your Future
Leyton is an international consulting firm that helps businesses leverage financial incentives to accelerate their growth and achieve long-lasting performance.
